Gensight Biologics SA

NEW
OTCPK:GSGTF (France)  
$ 0.090 (0%) 10:08 PM EST
At Loss
Market Cap:
$ 21.10M
Enterprise V:
$ 33.00M
Volume:
0
Avg Vol (2M):
400.00
Trade In:
Volume:
0
At Loss
Avg Vol (2M):
400.00

Business Description

Description
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
0.19
Equity-to-Asset
-3.02
Debt-to-Equity
-0.52
Debt-to-EBITDA
-1.48
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-6.48
Distress
Grey
Safe
Beneish M-Score
-193.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
12-1 Month Momentum %
-20.79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.39
Quick Ratio
0.39
Cash Ratio
0.19
Days Sales Outstanding
4501.67

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-68.3
Shareholder Yield %
-42.81

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin %
-1105500
Net Margin %
-1203600
EBITDA Margin %
-868800
FCF Margin %
-213880
OCF Margin %
-213880
ROA %
-136.96
ROIC %
-71.37
3-Year ROIIC %
1161.55
ROC (Joel Greenblatt) %
-1336.2
Name Current Vs Industry Vs History
EV-to-EBIT
-3.19
EV-to-EBITDA
-3.36
EV-to-Revenue
29229
EV-to-FCF
-3.19
Price-to-GF-Value
2.25
Earnings Yield (Greenblatt) %
-31.35
FCF Yield %
-48.83

Financials

GSGTF's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:GSGTF

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Gensight Biologics SA Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.005
EPS (TTM) ($) -0.093
Beta 2868.3956
3-Year Sharpe Ratio 0.58
3-Year Sortino Ratio 864.77
Volatility % 20.79
14-Day RSI -
14-Day ATR ($) 0.00426
20-Day SMA ($) 0.15006
12-1 Month Momentum % -20.79
52-Week Range ($) 0.09 - 0.24
Shares Outstanding (Mil) 234.47

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Gensight Biologics SA Filings

Filing Date Document Date Form
No Filing Data

Gensight Biologics SA Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Gensight Biologics SA Frequently Asked Questions

What is Gensight Biologics SA(GSGTF)'s stock price today?
The current price of GSGTF is $0.09. The 52 week high of GSGTF is $0.24 and 52 week low is $0.09.
When is next earnings date of Gensight Biologics SA(GSGTF)?
The next earnings date of Gensight Biologics SA(GSGTF) is .
Does Gensight Biologics SA(GSGTF) pay dividends? If so, how much?
Gensight Biologics SA(GSGTF) does not pay dividend.

Guru Commentaries on OTCPK:GSGTF

No articles.

Press Release

Subject Date
No Press Release

Articles on Gensight Biologics SA

No articles.

Headlines

See More
  • 1
No news.
  • 1